<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Hypersensitivity pneumonitis &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/hypersensitivity-pneumonitis/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Sat, 08 Aug 2026 04:43:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Hypersensitivity pneumonitis &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Efficacy of Prednisolone Metasulfobenzoate Sodium vs Placebo in Adults with Fibrotic Hypersensitivity Pneumonitis: A Randomized Controlled Trial</title>
		<link>https://clinicaltrials.eu/trial/efficacy-of-prednisolone-metasulfobenzoate-sodium-vs-placebo-in-adults-with-fibrotic-hypersensitivity-pneumonitis-a-randomized-controlled-trial/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 08 Aug 2026 04:43:18 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/efficacy-of-prednisolone-metasulfobenzoate-sodium-vs-placebo-in-adults-with-fibrotic-hypersensitivity-pneumonitis-a-randomized-controlled-trial/</guid>

					<description><![CDATA[A rare lung condition called fibrotic hypersensitivity pneumonitis occurs when the immune system reacts to inhaled particles, causing inflammation and scarring that make breathing difficult. The disease is usually identified by a team of specialists and can range from mild to moderate severity in adults who have not received prior treatment for the scarring form [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>A rare lung condition called <b>fibrotic hypersensitivity pneumonitis</b> occurs when the immune system reacts to inhaled particles, causing inflammation and scarring that make breathing difficult. The disease is usually identified by a team of specialists and can range from mild to moderate severity in adults who have not received prior treatment for the scarring form of the illness.</p>
<p>The study compares a steroid medication, <b>prednisolone</b> (provided as SOLUPRED 5 mg tablets), with a placebo to see whether the drug improves lung function over six months. Participants are randomly assigned to receive either the active drug or the placebo and take the assigned tablets daily. Visits are scheduled at the start of the study, after three months, six months, and one year to collect information and perform safety checks.</p>
<p>During the visits, lung capacity is measured with a test called <b>FVC</b>, which records the amount of air expelled in a forced breath, and gas‑exchange ability is assessed with <b>DLco</b>. Physical endurance is evaluated using the <b>6MWT</b>, where the distance walked in six minutes is recorded. Quality of life related to breathing is surveyed with the <b>SGRQ</b> questionnaire. Any side effects such as weight gain or changes in blood pressure are also monitored throughout the study.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
